RCS - Arecor Therapeutics - TETRIS PHARMA ANNOUNCES AGREEMENT WITH GOODLIFE

Arecor TherapeuticsAnnouncement

04/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230904:nRSD1916La&default-theme=true

RNS Number : 1916L  Arecor Therapeutics PLC  04 September 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

 

TETRIS PHARMA ANNOUNCES COMMERCIALISATION AGREEMENT WITH GOODLIFE

 

Cambridge, UK, 4 September 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
announces that subsidiary company, Tetris Pharma Ltd has established an
exclusive commercialisation agreement with Goodlife, who will act as sole
partner for the import, marketing and distribution of Ogluo® in the BeNeLux
region.

 

See full Tetris Pharma announcement below:

 

Tetris Pharma announces commercialisation agreement with Goodlife

 

Partnership to drive accelerated market adoption of Ogluo in BeNeLux region

 

4 September 2023 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a
subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC),
today announces that it has established an exclusive commercialisation
agreement with Goodlife, who will act as sole partner for the import,
marketing and distribution of Ogluo® (glucagon prefilled autoinjector pen) in
the BeNeLux region.

 

The Zorginstiuut Nederland (the National Healthcare Institute of The
Netherlands) has approved Ogluo® at the requested price on List 1B and
Goodlife is expected to launch the product in The Netherlands during H1 2024.

 

Sarah Howell, Chief Executive Officer at Arecor, said: "Goodlife provides the
commercial expertise and detailed understanding of regional market dynamics
that are essential for the Company's continued roll-out of Ogluo® and its
market adoption in the BeNeLux region. The upcoming launch in The Netherlands
adds to existing markets in the UK, Germany, Austria, Denmark and Norway, as
part of the planned on-going pan-European commercial roll-out for this
important product."

 

Koen Perenboom, Managing Director, Goodlife, said: "With more than a quarter
of a million people living with insulin-treated diabetes and at risk of severe
hypoglycaemia in The Netherlands, Ogluo is an important treatment option for
people with diabetes and their caregivers, that can provide them with the
confidence to manage severe hypoglycaemic events. This strategic collaboration
with Arecor symbolises our mutual commitment to provide every individual
patient excellent care."

 

About Ogluo®:

Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon in an
auto-injector for patients within the licenced indication living with diabetes
suffering from severe hypoglycaemia(1). Hypoglycaemia is a common and serious
complication of diabetes, particularly affecting people with diabetes on
insulin treatment. It is characterised by abnormally low blood sugar levels,
which can lead to cognitive impairment and in some severe cases, seizures,
loss of consciousness, coma and even death. It can have a profound effect on
the everyday lives of people with diabetes and their caregivers(2). The
European Commission granted the marketing authorization for Ogluo® on 11
February 2021.

 

1.      Ogluo SmPC

2.      Amiel, S.A. The consequences of
hypoglycaemia. Diabetologia 64, 963-970 (2021).
https://doi.org/10.1007/s00125-020-05366-3

 

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage
specialty pharmaceutical company with expertise in registering, marketing,
sales and the distribution of speciality hospital products across the UK and
Europe. Our experienced team has a proven history of building and growing
sales. Having secured distribution rights for already licensed products across
Europe, we have a portfolio of niche injectable products including Ogluo®, a
ready-to-use glucagon for emergency use to treat hypoglycaemia. We collaborate
with partners to provide patients with effective treatments and quality
healthcare by ensuring we deliver accountability, partnership and performance.
For further information, please visit www.tetrispharma.com
(http://www.tetrispharma.com) .

 

Goodlife is a privately owned pharmaceutical company with a focus on The
Netherlands, Belgium and Luxembourg. Goodlife believes that every patient
deserves excellent care that matches their individual needs, even if those
needs deviate from the norm.  With this in mind, we strive for customization
every day, by providing unique medicines, medical devices, dietary supplements
and supportive tools for individual patients in the BeNeLux. For more
information, please visit www.goodlifepharma.com
(http://www.goodlifepharma.com) .

 

-ENDS-

 

 

For more information, please contact:

 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Susan Lowther, Chief Financial Officer          Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Mo Noonan, Communications                       Tel: +44 (0) 7876 444977

                                                 Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Lindsey Neville     Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com

 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio. For further details
please see our website, www.arecor.com (http://www.arecor.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUBABUPWGMG